Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia

American Journal of Kidney Diseases

Volumn 42, Issue 1 SUPPL. 2, 2003, Pages 96-107

  Joy, Melanie S ^a   Finn, William F ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

End stage renal disease (ESRD); Hyperphosphatemia; Lanthanum carbonate; Phosphate binder

Indexed keywords

LANTHANUM CARBONATE; PHOSPHATE BINDING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NAUSEA; PARATHYROID HORMONE BLOOD LEVEL; PHASE 3 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; TITRIMETRY; VOMITING;

EID: 0038386468     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00554-7     Document Type: Article

References (25)

1. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
2. Parkinson I, Feest T, Ward M, Fawcett R, Kerr D: Fracturing dialysis osteodystrophy and dialysis encephalopathy: An epidemiological survey. Lancet 1:406-409, 1979
3. McGonigle R, Parsons V: Aluminum-induced anaemia in haemodialysis patients. Nephron 39:1-9, 1985
4. Alfrey AC, Legendre GR, Kaehny WD: The dialysis encephalopathy syndrome: Possible aluminum intoxication. N Engl J Med 294:184-188, 1976
5. Ihle B, Becker G, Kincaid-Smith P: Clinical and biochemical features of aluminum-related bone disease. Kidney Int Suppl 18:S80-S86, 1986
6. Schaefer K: Alternative phosphate binders: An update. Nephrol Dial Transplant 1:35-39, 1993
7. Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
8. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky EA: Magnesium carbonate as a phosphorus binder: A prospective, controlled, crossover study. Kidney Int 49:163-167, 1996
9. Chertow GM, Burke SK, Lazarus JM, et al: Poly[allylamine Hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
10. Bleyer AJ, Burke SK, Dillon M, et al: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694-701, 1999
11. Slatopolsky EA, Burke SK, Dillon MA: RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 55:299-307, 1999
12. Wexler L, Brundage B, Crouse J, et al: Coronary artery calcification: pathophysiology, epidemiology, imaging methods and clinical implications: A statement for health professionals from the American Heart Association. Circulation 94:1174-1192, 1996
13. US Renal Data System: USRDS 1998 Annual data report. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 1999
14. Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252, 2002
15. Graff L, Burnel D: A possible non-aluminum oral phosphate binder? A comparative study on dietary phosphate absorption. Res Commun Mol Pathol Pharmacol 90: 373-388, 1995
16. Graff L, Burnel D: Reduction of dietary phosphorus absorption by oral phosphorus binders. Res Commun Mol Pathol Pharmacol 90:389-401, 1995
17. Finn WF, Joy MS, Hladik GA: Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis. J Am Soc Nephrol 10:261A, 1999
18. Dewberry K, Fox JS, Stewart J, Murray JR, Hutchison AJ: Lanthanum carbonate: A novel non-calcium containing phosphate binder. J Am Soc Nephrol 8:560A, 1997
19. Hutchison AJ, Speake M, Dewberry K, Fox JS: Lanthanum carbonate: A novel non-calcium-containing phosphate binder in CAPD patients. Perit Dial Int 18:S38, 1998 (suppl 2)
20. Validation Report for Lanthanum in Blood Plasma by ICP-MS. Report March 10, 2000. Research Triangle Park, NC, Research Triangle Institute, 2000
21. Massry SG: New bone metabolism and disease in CKD guidelines. Presented at the Annual Meeting of the American Society of Nephrology, Philadelphia, PA, October/November 2002
22. Evans CH: Biochemistry of the Lanthanides, New York, NY, Plenum, 1990
23. Swanson AA, Truesdale AW: Elemental analysis in normal and cataractous human lens tissue. Biochem Biophys Res Commun 45: 1488-1496, 1971
24. Erametsa O, Sihvonen ML: Rare earth in the human body II. Yttrium and lanthanides in the spleen. Ann Med Exp Fenn 49:35-37, 1971
25. Xu J, Ling E-A: Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers. J Anat 184:227-237, 1994